Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results

Mayo Clinic Proceedings

Volumn 71, Issue 1, 1996, Pages 69-80

  Egan, Laurence J ^a   Sandborn, William J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; ICOSANOID; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ALOPECIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FOLATE METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; ULCERATIVE COLITIS;

EID: 0030069646     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.1.69     Document Type: Review

References (98)

1. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologie remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110:353-356
2. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sei 1993; 38:1851 1856
3. Chamiot-Prieur C, Lémann M, Mesnard B, Halphen M, Messing B, Modigliani R, et al. Treatment of refractory Crohn's disease (CD) with methotrexate (MTX) [abstract]. Gastroenterology 1993; 104:A680
4. Arora S, Katkov WN, Cooley J, Kemp A, Schapiro RH, Kelsey PB, et al. A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn's disease [abstract]. Gastroenterology 1992; 102:A591
5. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al (for the North American Crohn's Study Group Investigators). Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332:292-297
6. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982; 70:351360
7. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad SciUSA 1985; 82:4881-4885
8. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4carboxamide riboside and ribotide. Biochem J 1986; 236:193-200
9. Baggott JE, Morgan SL, Vaughn WH. Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis. Biochem J 1994; 300:627-629
10. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:1094-1104
11. Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells: selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest 1983; 72:773-778
12. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35:409-412
13. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36:795-803
14. Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993; 20:950-952
15. Joyce DA, Will RK, Huffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991; 50:913914
16. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833-841
17. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28:466-469
18. Galivan J, Rehder MC, KerwarS. Methotrexate in adjuvant arthritis. In: Cooper BA, Whitehead MV, editors. Chemistry and Biology of Pteridines. Berlin: Walter de Gruyter, 1986: 847-850
19. Otterness IG, Chang YH. Comparative study of cyclophosphamide, 6-mercaptopurine, azathioprine and methotrexate: relative effects on the humoral and the cellular immune response in the mouse. Clin Exp Immunol 1976; 26:346-354
20. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992:16:411-423
21. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologie effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95:49S-52S
22. Johnston C, Russell AS, Aaron S. The effect of in vivo and in vitro methotrexate on lymphocyte proliferation as measured by the uptake of tritiated thymidine and tritiated guanosine. Clin Exp Rheumatol 1988:6:391-393
23. Olsen NJ, Callahan LF, Pincus T. Immunologie studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987:30:481-488
24. Johnston CA, Russell AS, Kovithavongs T, Dasgupta M. Measures of immunologie and inflammatory responses in vitro in rheumatoid patients treated with methotrexate. J Rheumatol 1986; 13:294296
25. Olsen JN, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32:378385
26. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donors and spermidine. Arthritis Rheum 1990; 33:954-959
27. Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin l to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993; 31:667-674
28. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues [editorial]. J Rheumatol 1994; 21:1-5
29. Dieleman LA, Beagley KW, Elson CO. The effect of prednisolone, 5-aminosalicylic acid, 6-mercaptopurine and methotrexate on monocyte-derived inflammatory cytokine expression of human mononuclear cells [abstract]. Gastroenterology 1991; 100:A575
30. Sperling RI, Benincaso AI, Andersen RJ, Coblyn JS, Austen KF, Weinblatt ME. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992; 35:376-384
31. Barankiewicz J, Ronlov G, Jimenez R, Gruber HE. Selective adenosine release from human B but not T lymphoid cell line. J Biol Chem 1990:265:15738-15743
32. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sei U S A 1991; 88:24412445
33. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-2682
34. Asako H, Wolf RE, Granger DN. Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology 1993; 104:31-37
35. Eliakim R, Karmeli F, Chorev M, Okon F, Rachmilewitz D. Effect of drugs on colonie eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 1992; 27:968-972
36. Seeger DR. Cosalich DB, Smith JM, Hultquist ME. Analogs of pteroylglutamic acid. III. 4-Aminoderivatives. J Am Chem Soc 1949:71:1753-1758
37. Lippens RJ. Methotrexate. I. Pharmacology and pharmacokinetics. Am J Pediatr Hematol Oncol 1984; 6:379-395
38. Selhub J, Dhar GJ, Rosenberg IH. Gastrointestinal absorption of folates and antifolates. Pharmacol Ther 1983; 20:397-418
39. Zimmerman J. Folic acid transport in organ-cultured mucosa of human intestine: evidence for distinct carriers. Gastroenterology 1990; 99:964-972
40. Chungi VS. Bourne DW, Dittert LW. Drug absorption. VIII. Kinetics of GI absorption of methotrexate. J Pharm Sei 1978; 67:560561
41. Zimmerman J. Methotrexate transport in the human intestine: evidence for heterogeneity. Biochem Pharmacol 1992; 43:2377-2383
42. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987; 110:788-792
43. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974; 34:3487-3491
44. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20:1845-1849
45. Oguey D, Kolliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35:611-614
46. Kearney PJ, Light PA, Preece A, Mott MG. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1979; 3:117-120
47. Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53:475-477
48. Kremer JM, Hamilton RA, Petrillo GF. Stocker RP, Rynes RI, Davies J. Linearity of methotrexate pharmacokinetics in the dosage range used to treat rheumatoid arthritis [abstract]. Arthritis Rheum 1992 Sep; 35(Suppl):S 144
49. Balis FM, Mirro J Jr, Reaman GH, Evans WE, McCully C, Doherty KM, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988:6:1882-1886
50. Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:91-94
51. Huffman DH, Wan SH, Azarnoff DL, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973:14:572-579
52. Schröder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988; 21:145-149
53. Schröder H, Fogh K, Merlin T. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes. Cancer Chemother Pharmacol 1988; 21:150-155
54. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41:36-51
55. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983; 43:2342-2345
56. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res 1965; 25:1018-1024
57. Strum WB, Liem HH. Hepatic uptake, intracellular protein binding and biliary excretion of amethopterin. Biochem Pharmacol 1977; 26:1235-1240
58. McAnena OJ, Rossi M, Mehta BM, Daly JM. Alteration of methotrexate metabolism in rats by administration of an elemental liquid diet. I. Changes in drug enterohepatic circulation. Cancer 1987; 59:31-37
59. Charland SL, Bartlett D, Torosian MH. Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. JPEN J Parenter Enterai Nutr 1994; 18:45-49
60. Beck O, Seideman P, Wennberg M, Peterson C. Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid Chromatographie method. Ther DrugMonit 1991; 13:528-532
61. Ekstrom O, Andersen A, Warren DJ, Giercksky KE, Slordal L. Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. Cancer Chemother Pharmacol 1994; 34:297-301
62. Kozarek RA, Patterson DJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease: severe disease 3, drug therapy 2; seventh inning stretch [abstract]. Gastroenterology 1992; 102:A648
63. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106:494-499
64. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991; 20:317-331
65. Alcaron GS, Tracy 1C, Blackburn WD Jr. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32:671-676
66. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994; 23:310-327
67. Kozarek RA, Bredfeldt JE, Rosoff LE, Patterson DJ, Fenster LF. Does chronic methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? [abstract]. Gastroenterology 1991; 100:A221
68. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994 May; 20:513-528
69. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment. BrJDermatol 1980; 102:407-412
70. Nyfors A, Poulsen H. Liver biopsies for psoriatics related to methotrexate therapy. 2. Findings before and after methotrexate therapy in 88 patients: a blind study. Acta Pathol Microbiol Scand [A] 1976; 84:262-270
71. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 83:1337-1345
72. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32:121-127
73. Podurgiel BJ, McGill DB, Ludwig J, Taylor WF, Muller SA. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973; 48:787-792
74. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines-revised. J Am Acad Dermatol 1982; 6:145-155
75. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Fürst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37:316-328
76. Walker AM, Punch D, Dreyer NA, Tolman KG, Kremer JM, Alarcon GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36:329-335
77. Weinstein G, Roenigk H, Maibach H, Cosmides J, Halprin K, Millard M, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108:36-42
78. Newman M, Auerbach R, Feiner H, Holzman RS, Shupack J, Migdal P, et al. The role of liver biopsies in psoriatic patients receiving longterm methotrexate treatment: improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125:1218-1224
79. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: effects of long-term treatment in psoriasis. BrJ Dermatol 1994; 130:204-210
80. Gilbert SC, Klintmalm G, Menter A, Silverman A. Methotrexateinduced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this 'steroid-sparing'agent. Arch Intern Med 1990;150:889-891
81. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19:145-156
82. Trier JS. Morphological alterations induced by methotrexate in the mucosa of human proximal intestine. I. Serial observations by light microscopy. Gastroenterology 1962; 42:295-305
83. Phelan MJ, Taylor W, van Heyningen C, Williams E, Thompson RN. Intestinal absorption in patients with rheumatoid arthritis treated with methotrexate. Clin Rheumatol 1993; 12:223-225
84. Taylor SG HI, Hass GM, Crumrine JL, Slaughter DP. Toxic reactions of 4-amino-pteroylglutamic acid (aminopterin) in patients with far-advanced neoplastic disease. Cancer 1950; 3:493-503
85. Baker H. Intermittent high dose oral methotrexate therapy in psoriasis. BrJ Dermatol 1970; 82:65-69
86. Novak RA, Kessinger A. Methotrexate induced colitis. Nebr Med J 1976; 61:84-87
87. Uvizi J, Krajci A, Cerny K. Acute necrotizing colitis in a psoriatic treated by methotrexate. Cesk Dermatol 1977; 52:227-232
88. Atherton LD, Leib ES, Kaye MD. Toxic megacolon associated with methotrexate therapy. Gastroenterology 1984; 86:1583-1588
89. Halstad CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 1981; 305:15131517
90. Zimmerman J. Drug interactions in intestinal transport of folic acid and methotrexate: further evidence for the heterogeneity of folate transport in the human small intestine. Biochem Pharmacol 1992; 44:1839-1842
91. Nisar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. BrJ Rheumatol 1994; 33:651-654
92. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993; 20:263-267
93. Korstanje MJ, van Breda Vriesman CJ, van de Staak WJ. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 1990; 23:320-321
94. Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, et al. The effect of methotrexate on the bioavailability of oral 6mercaptopurine. Clin Pharmacol Ther 1987; 41:384-387
95. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992; 282:197-202
96. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26:234-237
97. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hématologie toxicity due to methotrexate therapy. Arthritis Rheum 1989;32:1592-1596
98. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32:677-681